Added to YB: 2025-10-22
Pitch date: 2025-09-03
WVE [bullish]
Wave Life Sciences Ltd.
+64.5%
current return
Author Info
No bio for this author
Company Info
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform.
Market Cap
$2.3B
Pitch Price
$8.00
Price Target
11.20 (-15%)
Dividend
N/A
EV/EBITDA
-17.65
P/E
-17.05
EV/Sales
19.70
Sector
Pharmaceuticals
Category
growth
Wave Life Sciences Ltd. - $WVE
WVE: Wave set to announce Phase 1b/2a results for WVE-006 (AATD) in coming days/weeks - success largely priced in but could position as best-in-class, generating $324M peak royalties to Wave via GSK deal. WVE-007 obesity asset targets novel INHBE pathway, synergistic with GLP-1s in preclinicals. Stock could gain +10-20% on WVE-006 success, +40% if WVE-007 proves viable in obesity market.
Read full article (16 min)